- The Competition Commission of India has approved Mankind Pharma’s acquisition of Bharat Serums and Vaccines for $1.64 billion.
- This acquisition will enhance Mankind Pharma’s position in the women’s health and fertility market.
Mankind Pharma has received approval from the Competition Commission of India (CCI) for the acquisition of Bharat Serums and Vaccines (BSV) for $1.64 billion. The transaction involves acquiring a 100% stake in BSV. This strategic move is seen as a significant step for Mankind Pharma, allowing it to bolster its position in the Indian women’s health and fertility drug market.
Mankind Pharma, a publicly listed firm, develops, manufactures, and markets a wide range of pharmaceutical finished dosage formulations. Through its subsidiaries, the company is also involved in the production and sale of active pharmaceutical ingredients (APIs) and intermediaries. The acquisition of BSV will enable Mankind to tap into high-entry barrier products in critical care, enhancing its capabilities in research and development.
Bharat Serums and Vaccines is a biopharmaceutical leader in several sectors, including women’s healthcare, assisted reproductive treatments, and emergency medicine. The acquisition, initially announced in July 2024, was made from the private equity firm Advent International.
Peter Ronco, CEO of Mankind Pharma, noted, “This acquisition marks a crucial development in our growth strategy, allowing us to meet the evolving needs of our customers in the healthcare sector.” The CCI ensures that such significant deals comply with regulations promoting fair competition and curtailing unfair business practices.
Overview of outsourcing trends 
